ARTICLE | Finance

Sprucely debut

Why Spruce believes $20 million series A could take it to pivotal testing

October 13, 2017 8:58 PM UTC

Spruce Biosciences Inc. emerged from stealth mode on Oct. 12, unveiling a $20 million series A round the company says will fund an ongoing Phase II study for a rare endocrine indication and could propel the program into Phase III testing.

The biotech closed the A round in May 2016; Novo Holdings A/S led the financing, which saw participation from RiverVest Venture Partners...